A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer

Clinical trial NCT03219333 · COMPLETED

Trial details

NCT number: NCT03219333
Sponsor: Astellas Pharma Inc
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Carcinoma, Transitional Cell Urinary Bladder Neoplasms Urologic Neoplasms Renal Pelvis Neoplasms Urothelial Cancer Ureteral Neoplasms Urethral Neoplasms

Start date: 2017-10-08
Primary completion: 2020-10-27
Enrollment: 219

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.